Results 111 to 120 of about 337,127 (342)
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Seminars in Cancer Biology, 2017 Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker.M. Dieci, N. Radosevic-Robin, S. Fineberg, G. G. Van den Eynden, N. Ternès, F. Penault-Llorca, G. Pruneri, Timothy D’alfonso, S. Demaria, C. Castañeda, Joselyn Sanchez, S. Badve, S. Michiels, V. Bossuyt, F. Rojo, Baljit Singh, T. Nielsen, G. Viale, Seong-Rim Kim, S. Hewitt, S. Wienert, S. Loibl, D. Rimm, F. Symmans, C. Denkert, S. Adams, S. Loi, R. Salgado +27 moresemanticscholar +1 more sourceTumor‐Derived Alpha‐1 Antitrypsin Promotes Liver Metastasis of Colorectal Cancer Through the Neutrophil Extracellular Traps–CCDC25 Pathway
Advanced Science, EarlyView.ABSTRACT
Liver metastasis is a leading cause of mortality in colorectal cancer (CRC), where the inflammatory tumor microenvironment, specifically neutrophil infiltration, significantly promotes metastatic colonization. This study reveals a pro‐metastatic role for alpha‐1 antitrypsin (A1AT) in CRC liver metastasis via a dual mechanism involving ...Qian Fei, Chunning Li, Lei Zhan, Xiaoyan Li, Yan Hui, Yue Jin, Jing Zhang, Lu Yang, Xin Sun, Xiaoxi Li, Qian Dong, Jingdong Zhang +11 morewiley +1 more sourceTumor‐Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development
Advanced Science, EarlyView.A single‐cell atlas of pancreatic ductal adenocarcinoma development reveals progressive ductal‐fibroblast‐immune crosstalk. Tumor‐derived LAMB3 drives the formation of immunosuppressive LRRC15+ fibroblasts through the ITGB1/FAK/MAPK/FOSL2 signaling. Glycolytic reprogramming upregulates LAMB3 and correlates with LRRC15+ fibroblast enrichment.Xuqing Shi, Hangqi Liu, Jianru Sun, Xiaoding Liu, Xinping Jv, Longyun Chen, Yuhan Zhang, Hui Zhang, Xudong Xing, Ruiyu Li, Xinyi Ke, Jun Wang, Xianglin Yin, Bohan Liu, Qixian Liu, Yuan Wang, Junliang Lu, Shiyi Liu, Junyi Pang, Yumeng Cai, Menghua Dai, Fan Bai, Huanwen Wu, Zhiyong Liang +23 morewiley +1 more sourceCD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes
OncoImmunology, 2017 CD69 is an early activation marker on the surface of T lymphocytes undergoing activation by cognate antigen. We observed intense expression of CD69 on tumor-infiltrating T-lymphocytes that reside in the hypoxic tumor microenvironment and hypothesized ...Sara Labiano, Florinda Meléndez-Rodríguez, Asís Palazón, Álvaro Teijeira, Saray Garasa, Iñaki Etxeberria, M. Ángela Aznar, Alfonso R. Sánchez-Paulete, Arantza Azpilikueta, Elixabet Bolaños, Carmen Molina, Hortensia de la Fuente, Patricia Maiso, Francisco Sánchez-Madrid, Manuel Ortiz de Landázuri, Julián Aragonés, Ignacio Melero +16 moredoaj +1 more sourceA Microbial Lipid‐ATP Synthase Axis Fuels NK Cell Antitumor Activity
Advanced Science, EarlyView.This study focuses on the mechanism by which gut microbiota‐derived outer membrane vesicles (OMVs) regulate NK cell antitumor activity. B. intestinalis is identified to decrease extra‐intestinal tumor growth via its OMVs enriched in sphingosine (SP).Kaiyuan Yu, Xinyu Sun, Wanxia Ma, Jianming Yang, Xuan Sun, Lisong Zhang, Yumeng Liu, Tianshu Ren, Qi Wang, Jingyu Wang, Xiao Li, Xianping Peng, Liu Yang, Junqiang Lv, Zhi Yao, Zhi‐Song Zhang, Quan Wang +16 morewiley +1 more sourceDose-Response Relationship of CD8+ Tumor Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
JAMA Oncology, 2017 Importance Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors.E. Goode, M. Block, K. Kalli, R. Vierkant, Wenqian Chen, Zachary C. Fogarty, A. Gentry-Maharaj, A. Tołoczko, A. Hein, Aliecia L. Bouligny, A. Jensen, A. Osorio, A. Hartkopf, A. Ryan, A. Chudecka-Głaz, A. Magliocco, A. Hartmann, A. Jung, B. Gao, B. Hernandez, B. Fridley, Bryan M McCauley, C. Kennedy, Chen Wang, C. Karpinskyj, C. B. de Sousa, D. Tiezzi, D. Wachter, E. Herpel, F. Taran, F. Modugno, G. Nelson, J. Lubiński, J. Menkiszak, J. Alsop, J. Lester, J. García-Donas, J. Nation, J. Hung, J. Palacios, J. Rothstein, J. Kelley, J. M. de Andrade, L. Robles-Díaz, M. Intermaggio, M. Widschwendter, M. Beckmann, M. Ruebner, M. Jimenez-Linan, N. Singh, O. Oszurek, P. Harnett, P. Rambau, P. Sinn, Philipp Wagner, P. Ghatage, Raghwa N. Sharma, R. Edwards, R. Ness, S. Orsulic, S. Brucker, S. Johnatty, T. Longacre, U. Eilber, V. McGuire, W. Sieh, Y. Natanzon, Zheng Li, A. Whittemore, A. Defazio, A. Staebler, B. Karlan, B. Gilks, D. Bowtell, E. Høgdall, F. J. Candido dos Reis, H. Steed, I. Campbell, J. Gronwald, J. Benítez, J. Koziak, J. Chang-Claude, K. Moysich, L. Kelemen, L. Cook, M. Goodman, M. García, P. Fasching, S. Kommoss, S. Deen, S. K. Kjaer, U. Menon, J. Brenton, P. Pharoah, G. Chenevix-Trench, D. Huntsman, S. Winham, M. Köbel, S. Ramus +98 moresemanticscholar +1 more sourcePharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade
Advanced Science, EarlyView.This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang +12 morewiley +1 more source
